Japan Lifeline (7575) Q4 2025 earnings summary

Executive summary

• Achieved record-high net sales of ¥56.6B (+10.2% YoY), operating profit of ¥12.3B (+13.2% YoY), and net profit of ¥9.3B (+24.0% YoY) for FYE3/2025, driven by strong core product performance and expansion in new therapeutic areas.

• Double-digit growth in both sales and profits, with all major business segments contributing; deferred tax assets recognized as a non-recurring item boosted net profit.

• Growth driven by strong performance in core EP/Ablation business and expansion in new therapeutic areas, offsetting reimbursement price reductions.

• Strategic focus on expanding neurovascular and gastrointestinal portfolios, maintaining high market share in core cardiac and vascular products.

• Revised upward medium-term targets for FY ending March 31, 2028, including net sales and EPS.

Financial highlights

• Gross profit margin held at 60.4% (+10bps YoY); operating margin improved to 21.8% (+60bps YoY); EPS rose to ¥131.43 (+33.1% YoY).

• Net sales: ¥56,610 million (+10.2% YoY); Operating profit: ¥12,326 million (+13.2% YoY); Net income: ¥9,317 million (+24.0% YoY).

• Basic EPS: ¥131.43 (vs. ¥98.73 prior year); ROE: 15.8%; ROA: 16.6%.

• Cash and cash equivalents at year-end: ¥11,014 million (down ¥1,654 million YoY), mainly due to inventory build-up and treasury share repurchases.

• Q4 net profit surged 67.3% YoY due to special items, despite flat operating profit from increased R&D spend.

Outlook and guidance

• FYE3/2026 guidance: net sales ¥59.3B (+4.8% YoY), operating profit ¥12.9B (+4.7% YoY), net profit ¥9.35B (+0.3% YoY), and EPS ¥133.30 (+1.4% YoY); all expected to reach new record highs.

• Growth to be led by core products and 30% YoY expansion in new therapeutic areas; prior year deferred tax asset will not recur.

• Gross margin expected at 59.7% (-70 bps YoY); operating margin to remain at 21.8%.

• Dividend per share forecasted at ¥54 (payout ratio 40.5%), with continued focus on shareholder returns and capital efficiency.

• Growth expected in EP/Ablation (+4.7%), Cardiovascular (+3.7%), Neurovascular (+20%), and Gastrointestinal (+40%).